Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_211_библиотеки_им_акад_М_И_Перельмана
.pdf
131
93. Coronavirus Disease 2019 (COVID19): A Systematic Review of Imaging
Findings in 919 Patients / S. Salehi, A. Abedi, S. Balakrishnan, A. Gholamrezanezhad //
American Journal of Roentgenology. – 2020. – Vol. 215. – P. 87-93.
94. Coronavirus disease 2019 (COVID-19): situation report 158 [Electronic
resource] / World Health Organization. – 2020. – Mode of access:
https://www.who.int/docs/ default-source/coronaviruse/situation-reports/20200626-
covid-19-sitrep-158.pdf? sfvrsn =1d1aae8a_2.
95. COVID-19 associated pneumonia despite repeatedly negative PCR-analysis
from oropharyngeal swabs / D. Hornuss, K. Laubner, C. Monasterio [et al.] // Deutsche
Medizinische Wochenschrift. – 2020. – Vol. 145, № 12. – P. 844-849.
96. COVID-19: combining antiviral and anti-inflammatory treatments /
J. Stebbing, A. Phelan, I. Griffin [et al.] // The Lancet Infectious Diseases. – 2020. – Vol.
20, № 4. – P. 400-402.
97. COVID-19, immune system response, hyperinflammation and repurposing
antirheumatic drugs / A. Tufan, A. Avanoğlu Güler, M. Matucci-Cerinic // Turkish
Journal of Medical Sciences. – 2020. – Vol. 50, № SI-1. – P. 620-632.
98. COVID-19 Is Distinct From SARS-CoV-2-Negative Community-Acquired
Pneumonia / Y. Zhou, S. Guo, Y. He [et al.] // Frontiers in Cellular and Infection
Microbiology. – 2020. – Vol. 10. – P. 322.
99. COVID-19 pneumonia: different respiratory treatments for different
phenotypes? / L. Gattinoni, D. Chiumello, P. Caironi [et al.] // Intensive Care Medicine.
– 2020. – Vol. 14. – P. 1-4.
100. COVID-19 Threat to the World: Current and Possible Diagnostic/Treatment
Strategies / M. Mughees, H. Chugh, S.H. Naqvi, S. Wajid // Critical Reviews in
Biomedical Engineering. – 2021. – Vol. 49, № 1. – P. 21-33.
101. Cytokine release syndrome / A. Shimabukuro-Vornhagen, P. Gödel,
M. Subklewe [et al.] // The Journal for ImmunoTherapy of Cancer. – 2018. – Vol. 6,
№ 1. – P. 56.
102. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor
antagonist tocilizumab may be the key to reduce mortality / C. Zhang, Z. Wu, J.-W. Li
https://t.me/med1917
132
[et al.] // International Journal of Antimicrobial Agents. – 2020. – Vol. 55, № 5. –
P. 105954.
103. Cytokine storm in COVID-19: from viral infection to immune responses,
diagnosis and therapy / Y. Jiang, L. Rubin, T. Peng [et al.] // International Journal of
Biological Sciences. – 2022. – Vol. 18, № 2. – P. 459-472.
104. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy /
C. Zanza, T. Romenskaya, A.C. Manetti [et al.] // Medicina (Kaunas). – 2022. – Vol. 58,
№ 2. – P. 144.
105. DNA methylation analysis of the angiotensin converting enzyme (ACE)
gene in major depression / P. Zill, T.C. Baghai, C. Schüle [et al.] // PLoS ONE. – 2012.
– Vol. 7. – P. e40479.
106. DNA methylation of candidate genes (ACE II, IFN-Γ , AGTR 1, CKG,
ADD1, SCNN1B and TLR2) in essential hypertension: A systematic review and
quantitative evidence synthesis / L. Holmes, A. Lim, C.R. Comeaux [et al.] //
International Journal of Environmental Research and Public Health. – 2019. – Vol. 16. –
P. 4829.
107. D’Silva, K.M. COVID-19 and Disease-Modifying Anti-rheumatic Drugs /
K.M. D’Silva, Z.S. Wallace // Current Rheumatology Reports. – 2021. – Vol. 23. – P. 28.
108. Effect of systemic glucocorticoids on mortality or mechanical ventilation in
patients with COVID-19 / M.J. Keller, E.A. Kitsis, S. Arora [et al.] // Journal of Hospital
Medicine. – 2020. – Vol. 15, № 8. – P. 489-493. – doi: 10.12788/jhm.3497.
109. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe
or critical coronavirus disease 2019: randomised controlled trial / V.C. Veiga,
J.A.G.G. Prats, D.L.C. Farias [et al.] // British Medical Journal. – 2021. – Vol. 372. –
P. 84.
110. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-
19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial / O. Hermine,
X. Mariette, P.L. Tharaux [et al.] // Journal of the American Medical Association. – 2021.
– Vol. 181, № 1. – P. 32-40.
https://t.me/med1917
133
111. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia / F. Song,
N. Shi, F. Shan [et al.] // Radiology. – 2020. – Vol. 295, № 1. – Р. 210-217.
112. Factors associated with COVID-19-related death using OpenSAFELY /
E.J. Williamson, A.J. Walker, K. Bhaskaran [et al.] // Nature. – 2020. – Vol. 584, № 7821.
– P. 430-436.
113. False-negative results of real-time reverse-transcriptase polymerase chain
reaction for Severe acute respiratory syndrome coronavirus 2: role of deep-learning-based
CT diagnosis and sights from two cases / D. Li, D. Wang, J. Dong [et al.] // Korean
Journal of Radiology. – 2020. – Vol. 21, № 4. – P. 505-508.
114. Forchette, L. A Comprehensive Review of COVID-19 Virology, Vaccines,
Variants, and Therapeutics / L. Forchette, W. Sebastian, T. Liu // Current Medical
Science. – 2021. – Vol. 41, № 6. – P. 1037-1051.
115. Initial CT findings and temporal changes in patients with the novel
coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China / Y. Pan,
H. Guan, S. Zhou [et al.] // European Radiology. – 2020. – Vol. 30, № 6. – P. 3306-3309.
116. International register “Dynamics analysis of comorbidities in SARS-CoV-2
survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes
in COVID-19 / G.P. Arutyunov, E.I. Tarlovskaya, A.G. Arutyunov [et al.] // Russian
Journal of Cardiology. – 2021. – Vol. 26, № 4. – P. 4470.
117. James, A.S. COVID-19 Diagnosis: Potential Impact of Isothermal
Amplification Technology to Reduce Community of SARS-CoV-2 / A.S. James,
J.I. Alawneh // Diagnostics (Basel). – 2020. – Vol. 10, № 6. – P. 399.
118. Kmietowicz, Z. Covid-19: WHO recommends baricitinib and sotrovimab to
treat patients / Z. Kmietowicz // British Medical Journal. – 2022. – Vol. 376. – P. 97.
119. Loop-Mediated Isothermal Amplification (LAMP): A Rapid, Sensitive,
Specific, and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of
COVID-19 Pandemic / R. Augustine, A. Hasan, S. Das [et al.] // Biology (Basel). – 2020.
– Vol. 9, № 8. – P. 182.
120. Loop-mediated isothermal amplification of DNA / T. Notomi, H. Okayama,
H. Masubuchi [et al.] // Nucleic Acids Research. – 2000. – Vol. 28, № 12. – P. E63.
https://t.me/med1917
134
121. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection /
Y.C. Hwang, R.M. Lu, S.C. Su [et al.] // Journal of Biomedical Science. – 2022. –
Vol. 29, № 1. – P. 1.
122. Novel Coronavirus Pneumonia Outbreak in 2019: Computed Tomographic
Findings in Two Cases / C.X. Lin, Z. Gong, Z. Xiao [et al.] // Korean Journal of
Radiology. – 2020. – Vol. 21, № 3. – Р. 365-368.
123. Profiling Early Humoral Response to Diagnose NovelCoronavirus Disease
(COVID-19) / L. Guo, L. Ren, S. Yang [et al.] // Clinical Infectious Diseases. – 2020. –
Vol. 71, № 15. – P. 778-785.
124. Prognostic factors for severity and mortality in patients infected with
COVID-19: A systematic review / A. Izcovich, M.A. Ragusa, F. Tortosa [et al.] // PLoS
One. – 2020. – Vol. 15, № 11. – P. e0241955.
125. Radiological findings from 81 patients with COVID-19 pneumonia in
Wuhan, China: a descriptive study / H. Shi, X. Han, N. Jiang [et al.] // The Lancet
Infectious Diseases. – 2020. – Vol. 20, № 4. – P. 425-434.
126. Rapid isothermal amplification and portable detection system for SARS-
CoV-2 / A. Ganguli, A. Mostafa, J. Berger [et al.] // Proceedings of the National Academy
of Sciences. – 2020. – Vol. 117, № 37. – P. 22727-22735.
127. Sensitivity of different RT-qPCR solutions for SARS-CoV-2 detection /
J. Alcoba-Florez, H. Gil-Campesino, D. Garcia-Martinez de Artola [et al.] // International
Journal of Infectious Diseases. – 2020. – Vol. 99. – Р. 190-192.
128. Severe COVID-19 with persistent respiratory failure-A retrospective cohort
study in a tertiary centre in Malaysia / С.K. Wong, L.C. Sia, N.Z.M. Ooi [et al.] // PLoS
One. – 2022. – Vol. 17, № 11. – P. e0276848.
129. Shelter from the cytokine storm: Healthy living is a vital preventative
strategy in the COVID-19 era / R. Arena, S. Bond, I.R. Calvo [et al.] // Progress in
Cardiovascular Diseases. – 2022. – Vol. 73. – P. 56-60.
130. Small Solitary Ground-Glass Nodule on CT as an Initial Manifestation of
Coronavirus Disease 2019 (COVID-19) Pneumonia / T. Xia, J. Li, J. Gao, X. Xu // Korean
Journal of Radiology. – 2020. – Vol. 21, № 5. – P. 545-549.
https://t.me/med1917
135
131. Sun, R. Mediastinal Emphysema, Giant Bulla, and Pneumothorax
Developed during the Course of COVID-19 Pneumonia / R. Sun, H. Liu, X. Wang //
Korean Journal of Radiology. – 2020. – Vol. 21, № 5. – P. 541-544.
132. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor
Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia /
D.S. Fomina, M.A. Lysenko, I.P. Beloglazova [et al.] // Pathogens and Immunity. –
2020. – Vol. 5, № 1. – P. 327-341.
133. The Institute for Fiscal Studies. Are some ethnic groups more vulnerable to
COVID-19 than others? [Electronic resource]. – 2020. – Mode of
access: https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-
vulnerable-to-covid-19-than-others/.
134. The species severe acute respiratory syndrome-related coronavirus:
classifying 2019-nCoV and naming it SARS-CoV-2 / Coronaviridae Study Group of the
International Committee on Taxonomy of Viruses // Nature Microbiology. – 2020. –
Vol. 5, № 4. – P. 536-544.
135. Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) [Electronic
resource]. – Mode of access: https://www.clinicaltrials.gov/ct2/show/NCT04317092.
136. Tofacitinib у пациентов, госпитализированных с пневмонией Covid-19 /
P.O. Guimarães, D. Quirk, R.H. Furtado [et al.] // The New England Journal of Medicine.
– 2021. – Vol. 385. – P. 406-415.
137. Zhang, Y.P. The epidemiological characteristics of an outbreak of 2019
novel coronavirus diseases (COVID-19) in China / Y.P. Zhang // Chinese journal of
Epidemiology. – 2020. – Vol. 41. – P. 145-151.
https://t.me/med1917
136
ПРИЛОЖЕНИЯ
Приложение А
(справочное)
Патент № 2770357
https://t.me/med1917
137
Приложение Б
(справочное)
Свидетельство о регистрации программы ЭВМ № 2021668598
https://t.me/med1917
138
https://t.me/med1917
139
Приложение В
(справочное)
Свидетельство о регистрации программы ЭВМ № 2022611745
https://t.me/med1917
140
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана